Pharma

NeoGenomics Nabs Human Longevity's Oncology Division for $37M

5 days ago   |   By Xconomy

The genetic testing company NeoGenomics has acquired Human Longevity's Oncology Division, which provides next-generation sequencing services. The division of San Diego-based Human Longevity generated approximately $10 million in revenue in 2019-an amount NeoGenomics thinks it can grow by nearly 50 percent, says Charlie Eidson, investor relations and corporate development analyst, NeoGenomics. Additionally, the oncology division closed out the year with a backlog of approximately $15 million worth of signed contracts. According to Eidson, the deal boosts NeoGenomics's pharma services and...
Read more ...

 


Search by Tags

   Pharma      Genetics      Genomics      Genome      National      National blog main      San Diego      San Diego blog main      Acquisitions      Biotech      Diganostics      Exact Sciences      Healthcare      Human Longevity      Life Sciences      NeoGenomics      Oncology  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they're “undruggable.”... Read more ...

AveXis Inc.: Research Associate III

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Student Assistant

Mirati Therapeutics: Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations San... Read more ...

Inhibition of lignification of Zizania latifolia with radio frequency...

Zizania latifolia is easily lignified after harvesting, leading to the degradation of food quality and commercial value. Thus, this study evaluated the effect of radio... Read more ...

Performance difference of graph-based and alignment-based hybrid error...

The error-prone third-generation sequencing long reads can be corrected by the high-quality second-generation sequencing short reads, which is referred to as hybrid error... Read more ...

CHROMATIX: computing the functional landscape of many-body chromatin...

Chromatin interactions are important for gene regulation and cellular specialization. Emerging evidence suggests many-body spatial interactions play important roles in... Read more ...

Bachem: Validation Engineer II, QA

Bachem: Your Responsibilities The Validation Engineer II fulfills a critical role in GMP operations. This individual must plan and execute validation studies, Vista, CA, US ... Read more ...

AveXis Inc.: Senior Scientist, Molecular Biology

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Talent Partner

Mirati Therapeutics: Reporting to the Head of Business, Culture and Talent this role will be partner with C-Level executive(s) and their staff. This role will be responsib San... Read more ...

Selective inhibition of matrix metalloproteinase 10 with a single-domain...

Since their discovery, the matrix metalloproteinase family of proteases have been considered as therapeutic targets in numerous diseases and disorders. Unfortunately, clinical... Read more ...